CERVICAL CANCER IN THE REPUBLIC OF NORTH MACEDONIA (2014-2021): POTENTIAL DIFFERENCES BY AGE AND PLACE OF RESIDENCE
Keywords:
cervical cancer, morbidity, mortality; urban, ruralAbstract
Cervical cancer remains an important problem affecting more than half a million women across the globe each year. This study aims to illustrate the demographic (age) and geographic (rural/urban place of residence) differences in cervical cancer incidence rates in the Republic of North Macedonia. For this reason, a cross-sectional analytical study of 1817 cervical cancer patients registered in the period from 2014 through 2021 was conducted. Analysis of newly diagnosed cases of cervical cancer (2014-2021) indicated an upward trend by place of residence and age groups. The geographic (rural/urban) analysis indicated that 1309(72.7%) cases were from urban areas, and 492(27.3%) from rural areas. The majority or 1261(69.4%) were aged ≥50 years. The proportion of women aged under 50 was significantly lower - 556(30.6%), but liable to increase. In selected statistical regions, analysis of several years did not indicate a significant urban/rural difference in the percentage of newly diagnosed cases of cervical cancer.
Although a significant part of the burden of cervical cancer can be alleviated through the HPV vaccination and timely screening, focused research on the geographic and socio-demographic specificities of the population must be conducted. Such research would provide a greater understanding of the nature of regional and sociodemographic disparities, which would in turn allow for the creation and improvement of programs for prevention, diagnosis and timely treatment of cervical cancer.
References
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Heal [Internet] 2023; 11(2): e197-e206. doi: 10.1016/S2214-109X(22)00501-0.
Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet [Internet] 2020; 395(10224): 591-603. doi: 10.1016/S0140-6736(20)30157-4.
WHO. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020.
La Torre G, de Waure C, Chiaradia G, Mannocci A, Ricciardi W. HPV vaccine efficacy in preventing persistent cervical HPV infection: A systematic review and meta-analysis. Vaccine [Internet] 2007; 25(50): 8352-8358. doi: 10.1016/j.vaccine.2007.09.027.
Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and Safety of Prophylactic Vaccines against Cervical HPV Infection and Diseases among Women: A Systematic Review & Meta-Analysis. BMC Infect Dis [Internet] 2011; 11(1): 13. doi: 10.1186/1471-2334-11-13.
Lehtinen M, Dillner J. Clinical trials of human papillomavirus vaccines and beyond. Nat Rev Clin Oncol [Internet]. 2013; 10(7): 400-410. doi: 10.1038/nrclinonc.2013.84.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin [Internet] 2018; 68(6): 394-424. doi: 10.3322/caac.21492.
Spayne J, Hesketh T. Estimate of global human papillomavirus vaccination coverage: analysis of country-level indicators. BMJ Open [Internet] 2021; 11(9): e052016. doi: 10.1136/bmjopen-2021-052016.
Yang M, Du J, Lu H, Xiang F, Mei H, Xiao H. Global trends and age-specific incidence and mortality of cervical cancer from 1990 to 2019: an international comparative study based on the Global Burden of Disease. BMJ Open [Internet] 2022; 12(7): e055470. doi: 10.1136/bmjopen-2021-055470.
Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, et al. Management and Care of Women with Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. J Glob Oncol [Internet] 2016; 2(5): 311-340. doi: 10.1200/JGO.2016.003954. eCollection 2016 Oct.
Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah K V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol [Internet] 2002; 55(4): 244-265. doi: 10.1136/jcp.55.4.244.
Jansen EEL, Zielonke N, Gini A, Anttila A, Segnan N, Vokó Z, et al. Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review. Eur J Cancer [Internet] 2020; 127: 207-223. doi: 10.1016/j.ejca.2019.12.013. Epub 2020 Jan 21.
Sengayi-Muchengeti M, Joko-Fru WY, Miranda-Filho A, Egue M, Akele-Akpo MT, N'da G, et al. Cervical cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index: A population-based registry study. Int J Cancer 2020; 147(11): 3037-3048. doi: 10.1002/ijc.33120.
Vu M, Yu J, Awolude OA, Chuang L. Cervical cancer worldwide. Curr Probl Cancer [Internet] 2018; 42(5): 457-465. doi: 10.1016/j.currproblcancer.2018.06.003.
Vaccarella S, Lortet-Tieulent J, Plummer M, Franceschi S, Bray F. Worldwide trends in cervical cancer incidence: Impact of screening against changes in disease risk factors. Eur J Cancer [Internet] 2013; 49(15): 3262-3273. doi: 10.1016/j.ejca.2013.04.024.
Simms KT, Steinberg J, Caruana M, Smith MA, Lew J-B, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol [Internet] 2019; 20(3): 394-407. doi: 10.1016/S1470-2045(18)30836-2.
Castanon A, Sasieni P. Is the recent increase in cervical cancer in women aged 20-24 years in England a cause for concern? Prev Med (Baltim) [Internet] 2018; 107: 21-28. doi: 10.1016/j.ypmed.2017.12.002.
Liu T, Song Y, Chen R, Zheng R, Wang S, Li L. Solid fuel use for heating and risks of breast and cervical cancer mortality in China. Environ Res [Internet]. 2020; 186: 109578. doi: 10.1016/j.envres.2020.109578.
Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine [Internet] 2006; 24(Suppl 3): S71-S77. doi: 10.1016/j.vaccine.2006.05.121.
The Lancet. Cervical cancer: unequal progress. Lancet [Internet] 2019; 393(10167): 104. doi: 10.1016/S0140-6736(19)30003-0.
Vale DB, Teixeira JC, Bragança JF, Derchain S, Sarian LO, Zeferino LC. Elimination of cervical cancer in low‐ and middle‐income countries: Inequality of access and fragile healthcare systems. Int J Gynecol Obstet [Internet] 2021; 152(1): 7-11. doi: 10.1002/ijgo.13458.
Shi J-F, Canfell K, Lew J-B, Qiao Y-L. The burden of cervical cancer in China: Synthesis of the evidence. Int J Cancer [Internet] 2012; 130(3): 641-652. doi: 10.1002/ijc.26042.
Palacio-Mejía LS, Rangel-Gómez G, Hernández-Avila M, Lazcano-Ponce E. Cervical cancer, a disease of poverty: mortality differences between urban and rural areas in Mexico. Salud Publica Mex [Internet] 2003; 45(Suppl 3): 315-325. doi: 10.1590/s0036-36342003000900005.
Antinyan A, Bertoni M, Corazzini L. Cervical cancer screening invitations in low and middle income countries: Evidence from Armenia. Soc Sci Med [Internet] 2021; 273: 113739. doi: 10.1016/j.socscimed.2021.113739.
Piñeros M, Saraiya M, Baussano I, Bonjour M, Chao A, Bray F. The role and utility of population-based cancer registries in cervical cancer surveillance and control. Prev Med (Baltim) [Internet] 2021; 144: 106237. doi: 10.1016/j.ypmed.2020.106237.
Downloads
Published
Versions
- 2023-07-06 (2)
- 2023-06-16 (1)
